

Yehuda Carmeli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11330148/yehuda-carmeli-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

217
papers

20,828
citations

70
h-index

142
g-index

225
ext. papers

24,200
ext. citations

7.9
avg, IF

6.56
L-index

#	Paper	IF	Citations
217	Carriage of vancomycin-resistant in infants following an outbreak in the neonatal intensive care unit: time to clearance of carriage and use of molecular methods to detect colonization.. <i>Infection Control and Hospital Epidemiology</i> , 2022 , 1-4	2	
216	Multicenter, Prospective Validation of a Phenotypic Algorithm to Guide Carbapenemase Testing in Carbapenem-Resistant Using the ERACE-PA Global Surveillance Program.. <i>Open Forum Infectious Diseases</i> , 2022 , 9, ofab617	1	1
215	Hospital-Onset Bloodstream Infections Caused by Eight Sentinel Bacteria: A Nationwide Study in Israel, 2018-2019. <i>Microorganisms</i> , 2022 , 10, 1009	4.9	0
214	Analysis of four carbapenem-resistant outbreaks using Fourier-transform infrared spectroscopy.. <i>Infection Control and Hospital Epidemiology</i> , 2022 , 1-3	2	1
213	A multi-institutional outbreak of New Delhi metallo-β-lactamase-producing with subsequent acquisition of the carbapenemase gene. <i>Infection Control and Hospital Epidemiology</i> , 2021 , 42, 1124-1127		
212	Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity. <i>BMC Infectious Diseases</i> , 2021 , 21, 309	4	1
211	Effect of a national policy of universal masking and uniform criteria for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) exposure on hospital staff infection and quarantine. <i>Infection Control and Hospital Epidemiology</i> , 2021 , 1-7	2	5
210	Antibiotic exposure and the risk of hospital-acquired diarrhoea and <i>Clostridioides difficile</i> infection: a cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2182-2185	5.1	2
209	The Israeli national policy for discontinuation of isolation of carbapenem-resistant Enterobacterales carriers by carbapenemase type: a retrospective cohort study. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 1518.e1-1518.e3	9.5	0
208	National Policy for Carbapenem-Resistant Enterobacteriaceae (CRE) Clearance and Discontinuation of Contact Precautions for CRE Carriers in Post-Acute Care Hospitals in Israel: Impact on Isolation-Days and New Acquisitions. <i>Clinical Infectious Diseases</i> , 2021 , 72, 829-835	11.6	0
207	<i>Citrobacter telavivum</i> sp. nov. with chromosomal mcr-9 from hospitalized patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021 , 40, 123-131	5.3	7
206	Surgical antibiotic prophylaxis in patients colonized with multidrug-resistant Gram-negative bacteria: practical and conceptual aspects. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, i40-i46	5.1	2
205	The effect of prophylaxis with ertapenem versus cefuroxime/metronidazole on intestinal carriage of carbapenem-resistant or third-generation-cephalosporin-resistant Enterobacterales after colorectal surgery. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 1481-1487	9.5	2
204	The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant <i>Pseudomonas aeruginosa</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021 , 40, 2533-2541	5.3	13
203	Evaluation of the MICRONAUT MIC-strip colistin assay for colistin susceptibility testing of carbapenem-resistant <i>Acinetobacter baumannii</i> and Enterobacterales. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021 , 100, 115391	2.9	
202	Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 1989-2034	6.2	10
201	Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 2399-2414	6.2	1

200	Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> : Implications for Dose Optimization. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0120421	5.9	1
199	Risk of SARS-CoV-2 transmission following exposure during dental treatment - A national cohort study. <i>Journal of Dentistry</i> , 2021 , 113, 103791	4.8	2
198	Elderly bedridden patients with dementia use over one quarter of resources in internal medicine wards in an Israeli hospital. <i>Israel Journal of Health Policy Research</i> , 2020 , 9, 21	1.7	4
197	Fourier Transform Infrared Spectroscopy Is a New Option for Outbreak Investigation: a Retrospective Analysis of an Extended-Spectrum-Beta-Lactamase-Producing <i>Klebsiella pneumoniae</i> Outbreak in a Neonatal Intensive Care Unit. <i>Journal of Clinical Microbiology</i> , 2020 , 58,	9.7	14
196	A silent outbreak of vancomycin-resistant <i>Enterococcus faecium</i> in a neonatal intensive care unit. <i>Antimicrobial Resistance and Infection Control</i> , 2020 , 9, 87	6.2	6
195	Metagenomic Characterization of Gut Microbiota of Carriers of Extended-Spectrum Beta-Lactamase or Carbapenemase-Producing Enterobacteriaceae Following Treatment with Oral Antibiotics and Fecal Microbiota Transplantation: Results from a Multicenter Randomized Trial.	4.9	6
194	In vivo Fitness of Strains in Murine Infection Is Associated with International Lineage II-rep-2 and International Lineage III Clones Showing High Case Fatality Rates in Human Infections. <i>Microorganisms</i> , 2020 , 8,	4.9	2
193	Detecting carbapenem-resistant (CRAB) carriage: Which body site should be cultured?. <i>Infection Control and Hospital Epidemiology</i> , 2020 , 41, 965-967	2	7
192	Performance of Rapid Polymyxin NP and Rapid Polymyxin Acinetobacter for the detection of polymyxin resistance in carbapenem-resistant <i>Acinetobacter baumannii</i> and Enterobacterales. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1484-1490	5.1	3
191	Reply to Apisarnthanarak and Apisarnthanarak. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2025	11.6	
190	Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes. <i>Clinical Microbiology and Infection</i> , 2020 , 26, 1185-1191	9.5	18
189	Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance. <i>ELife</i> , 2020 , 9,	8.9	7
188	Utilising sigmoid models to predict the spread of antimicrobial resistance at the country level. <i>Eurosurveillance</i> , 2020 , 25,	19.8	1
187	<i>Clostridium difficile</i> -associated disease and <i>Helicobacter pylori</i> seroprevalence: A case-control study. <i>Helicobacter</i> , 2020 , 25, e12668	4.9	0
186	Reply to Wilson et al. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1358-1359	11.6	
185	Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2599-2607	11.6	5
184	A National Intervention to Reduce Undesirable Urinary Tract Events in Internal Medicine Wards. <i>Infection Control and Hospital Epidemiology</i> , 2020 , 41, s98-s98	2	
183	Integrated chromosomal and plasmid sequence analyses reveal diverse modes of carbapenemase gene spread among. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 25043-25054	11.5	31

182	Rapid identification of capsulated <i>Acinetobacter baumannii</i> using a density-dependent gradient test. <i>BMC Microbiology</i> , 2020 , 20, 285	4.5	4
181	Personalized Ertapenem Prophylaxis for Carriers of Extended-spectrum β -Lactamase-producing Enterobacteriaceae Undergoing Colorectal Surgery. <i>Clinical Infectious Diseases</i> , 2020 , 70, 1891-1897	11.6	8
180	Trends in antimicrobial resistance in Israel, 2014-2017. <i>Antimicrobial Resistance and Infection Control</i> , 2019 , 8, 96	6.2	9
179	Zero or More: Methodological Challenges of Counting and Estimating Deaths Related to Antibiotic-resistant Infections. <i>Clinical Infectious Diseases</i> , 2019 , 69, 2029-2034	11.6	4
178	Success of a National Intervention in Controlling Carbapenem-resistant Enterobacteriaceae in Israel's Long-term Care Facilities. <i>Clinical Infectious Diseases</i> , 2019 , 68, 964-971	11.6	18
177	Likelihood of persistent carriage of carbapenem-resistant <i>Acinetobacter baumannii</i> on readmission in previously identified carriers. <i>Infection Control and Hospital Epidemiology</i> , 2019 , 40, 1188-1190	2	1
176	External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant <i>Klebsiella pneumoniae</i> bacteraemia cohort: the prognostic significance of colistin resistance. <i>International Journal of Antimicrobial Agents</i> , 2019 , 54, 442-448	14.3	6
175	Antimicrobial use trends, Israel, 2012 to 2017. <i>Eurosurveillance</i> , 2019 , 24,	19.8	3
174	Droplet aerosol dissemination of carbapenem-resistant <i>Acinetobacter baumannii</i> surrounding ventilated patients. <i>Infection Control and Hospital Epidemiology</i> , 2019 , 40, 365-367	2	9
173	Carriage of Extended-spectrum Beta-lactamase-producing Enterobacteriaceae and the Risk of Surgical Site Infection After Colorectal Surgery: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1699-1704	11.6	24
172	Treatment Outcomes of Colistin- and Carbapenem-resistant <i>Acinetobacter baumannii</i> Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2019 , 69, 769-776	11.6	58
171	The possibility of transmitting infections with vaginal ultrasound probes: why the guidelines must be met. <i>Israel Medical Association Journal</i> , 2019 , 21, 568-569	0.9	
170	Colistin versus colistin plus meropenem for severe infections AuthorsSreply. <i>Lancet Infectious Diseases, The</i> , 2018 , 18, 495-496	25.5	
169	Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing <i>Escherichia coli</i> and ESBL-Producing <i>Klebsiella pneumoniae</i> . <i>Infection Control and Hospital Epidemiology</i> , 2018 , 39, 660-667	2	29
168	Risk factors for recurrent <i>Clostridium difficile</i> infection in a tertiary hospital in Israel. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018 , 37, 1281-1288	5.3	6
167	Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. <i>Lancet Infectious Diseases, The</i> , 2018 , 18, 391-400	25.5	255
166	Lessons From an Outbreak of Varicella Infection in Pediatric Hemato-oncology Patients. <i>Pediatric Infectious Disease Journal</i> , 2018 , 37, 649-653	3.4	7
165	Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. <i>Lancet Infectious Diseases, The</i> , 2018 , 18, 318-327	25.5	1815

164	fecal toxin level is associated with disease severity and prognosis. <i>United European Gastroenterology Journal</i> , 2018 , 6, 773-780	5.3	19
163	The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study. <i>Clinical Infectious Diseases</i> , 2018 , 67, 1815-1823	11.6	18
162	Does <i>Acinetobacter baumannii</i> Serve as a Source for bla Dissemination into Enterobacteriaceae in Hospitalized Patients?. <i>Microbial Drug Resistance</i> , 2018 , 24, 150-153	2.9	4
161	Estimating the number of infections caused by antibiotic-resistant <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> in 2014: a modelling study. <i>The Lancet Global Health</i> , 2018 , 6, e969-e979	13.6	47
160	Israeli National Policy for Carbapenem-Resistant Enterobacteriaceae Screening, Carrier Isolation and Discontinuation of Isolation. <i>Infection Control and Hospital Epidemiology</i> , 2018 , 39, 85-89	2	18
159	The impact of antibiotic use on transmission of resistant bacteria in hospitals: Insights from an agent-based model. <i>PLoS ONE</i> , 2018 , 13, e0197111	3.7	29
158	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 906-913	5.1	36
157	Epidemiology and control measures of outbreaks due to antibiotic-resistant organisms in Europe (EMBARGO): a systematic review protocol. <i>BMJ Open</i> , 2017 , 7, e013634	3	7
156	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. <i>Lancet Infectious Diseases</i> , 2017 , 17, 726-734	25.5	268
155	Evolution and dissemination of the <i>Klebsiella pneumoniae</i> clonal group 258 throughout Israeli post-acute care hospitals, 2008-13. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2219-2224	5.1	12
154	Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	115
153	Incidence and Risk Factors for Community and Hospital Acquisition of <i>Clostridium difficile</i> Infection in the Tel Aviv Sourasky Medical Center. <i>Infection Control and Hospital Epidemiology</i> , 2017 , 38, 912-920	2	11
152	Carbapenem-Resistant Enterobacteriaceae: A Strategic Roadmap for Infection Control. <i>Infection Control and Hospital Epidemiology</i> , 2017 , 38, 580-594	2	50
151	Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae - Authors Reply. <i>Lancet Infectious Diseases</i> , 2017 , 17, 1020-1021	25.5	4
150	The Impact of a Carbapenem-Resistant Enterobacteriaceae Outbreak on Facilitating Development of a National Infrastructure for Infection Control in Israel. <i>Clinical Infectious Diseases</i> , 2017 , 65, 2144-2149	11.6	11
149	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. <i>International Journal of Antimicrobial Agents</i> , 2017 , 50, 664-672	14.3	8
148	Gentamicin- and Ciprofloxacin-Resistant Enterobacteriaceae in Cattle Farms in Israel: Risk Factors for Carriage and the Effect of Microbiological Methodology on the Measured Prevalence. <i>Microbial Drug Resistance</i> , 2017 , 23, 660-665	2.9	0
147	Occurrence of carbapenemase-producing <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. <i>Lancet Infectious Diseases</i> , 2017 , 17, 153-163	25.5	349

146	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort. <i>Clinical Infectious Diseases</i> , 2017 , 65, 1615-1623	11.6	33
145	A mathematical model of <i>Clostridium difficile</i> transmission in medical wards and a cost-effectiveness analysis comparing different strategies for laboratory diagnosis and patient isolation. <i>PLoS ONE</i> , 2017 , 12, e0171327	3.7	4
144	Molecular types and antimicrobial susceptibility patterns of <i>Clostridium difficile</i> isolates in different epidemiological settings in a tertiary care center in Israel. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016 , 86, 450-454	2.9	5
143	Ceftazidime-avibactam in ceftazidime-resistant infections. <i>Lancet Infectious Diseases</i> , 2016 , 16, 997-998	9.8	1
142	Outbreak of adenovirus type 55 infection in Israel. <i>Journal of Clinical Virology</i> , 2016 , 78, 31-5	14.5	25
141	Draft Genome Sequences of Two Multidrug-Resistant Extended-Spectrum- β -Lactamase-Producing <i>Klebsiella pneumoniae</i> Strains Causing Bloodstream Infections. <i>Genome Announcements</i> , 2016 , 4,		1
140	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1672-80	5.1	33
139	Comparative Study of a Novel Biochemical Assay, the Rapidec Carba NP Test, for Detecting Carbapenemase-Producing Enterobacteriaceae. <i>Journal of Clinical Microbiology</i> , 2016 , 54, 453-6	9.7	21
138	Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 460-3	5.1	23
137	Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. <i>BMJ Open</i> , 2016 , 6, e009956	3	34
136	Risk Factors for Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae (CP-CRE) Acquisition Among Contacts of Newly Diagnosed CP-CRE Patients. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 1219-25	2	24
135	Dissemination of the blaKPC gene by clonal spread and horizontal gene transfer: comparative study of incidence and molecular mechanisms. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2143-6	5.1	29
134	Prevalence and risk factors for carriage of extended-spectrum β -lactamase-producing Enterobacteriaceae among patients prior to bowel surgery. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016 , 85, 377-380	2.9	9
133	A Multinational, Preregistered Cohort Study of β -Lactam/ β -Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 4159-69	5.9	96
132	Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. <i>Lancet Infectious Diseases</i> , 2016 , 16, 661-673	25.5	233
131	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 1362-1371	6.4	66
130	Prevalence and risk factors for colonization with methicillin resistant <i>Staphylococcus aureus</i> and other <i>Staphylococci</i> species in hospitalized and farm horses in Israel. <i>Preventive Veterinary Medicine</i> , 2015 , 122, 135-44	3.1	14
129	Prevalence, Risk Factors, and Transmission Dynamics of Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae: a National Survey of Cattle Farms in Israel in 2013. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 3515-21	9.7	14

128	Persistence of <i>Klebsiella pneumoniae</i> ST258 as the predominant clone of carbapenemase-producing Enterobacteriaceae in post-acute-care hospitals in Israel, 2008-13. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 89-92	5.1	51
127	Cost Analysis of an Intervention to Prevent Methicillin-Resistant <i>Staphylococcus Aureus</i> (MRSA) Transmission. <i>PLoS ONE</i> , 2015 , 10, e0138999	3.7	8
126	Incidence of carbapenem-resistant gram negatives in Italian transplant recipients: a nationwide surveillance study. <i>PLoS ONE</i> , 2015 , 10, e0123706	3.7	52
125	Effect of Resistance Mechanisms on the Inoculum Effect of Carbapenem in <i>Klebsiella pneumoniae</i> Isolates with Borderline Carbapenem Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 5014-7	5.9	23
124	Mix and match of KPC-2 encoding plasmids in Enterobacteriaceae-comparative genomics. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014 , 79, 255-60	2.9	28
123	An ongoing national intervention to contain the spread of carbapenem-resistant enterobacteriaceae. <i>Clinical Infectious Diseases</i> , 2014 , 58, 697-703	11.6	157
122	Infection control and prevention measures to reduce the spread of vancomycin-resistant enterococci in hospitalized patients: a systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1185-92	5.1	85
121	Emergence of VIM-producing <i>Aeromonas caviae</i> in Israeli hospitals. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1211-4	5.1	16
120	Biofilm formation and susceptibility to gentamicin and colistin of extremely drug-resistant KPC-producing <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1027-34	5.1	54
119	Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management. <i>Annals of the New York Academy of Sciences</i> , 2014 , 1323, 22-42	6.5	142
118	Development and validation of a multiplex PCR assay for identification of the epidemic ST-258/512 KPC-producing <i>Klebsiella pneumoniae</i> clone. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014 , 78, 12-5	2.9	27
117	A national intervention to prevent the spread of carbapenem-resistant Enterobacteriaceae in Israeli post-acute care hospitals. <i>Infection Control and Hospital Epidemiology</i> , 2014 , 35, 802-9	2	33
116	Combination therapy for carbapenem-resistant Gram-negative bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2305-9	5.1	148
115	Geographical variability in the likelihood of bloodstream infections due to gram-negative bacteria: correlation with proximity to the equator and health care expenditure. <i>PLoS ONE</i> , 2014 , 9, e114548	3.7	31
114	Effect of an investigational vaccine for preventing <i>Staphylococcus aureus</i> infections after cardiothoracic surgery: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 1368-78	27.4	249
113	Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 5104-11	5.9	166
112	Epidemiological and microbiological characteristics of an outbreak caused by OXA-48-producing Enterobacteriaceae in a neonatal intensive care unit in Jerusalem, Israel. <i>Journal of Clinical Microbiology</i> , 2013 , 51, 2926-30	9.7	32
111	Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance. <i>Clinical Microbiology Reviews</i> , 2013 , 26, 289-307	34	109

110	Detection of the plasmid-mediated KPC-2 carbapenem-hydrolysing enzyme in three unusual species of the Enterobacteriaceae family in Israel. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 719-20 ⁵¹	16
109	A swordless knight: epidemiology and molecular characteristics of the blaKPC-negative sequence type 258 <i>Klebsiella pneumoniae</i> clone. <i>Journal of Clinical Microbiology</i> , 2012 , 50, 3180-5	9.7 36
108	Controlling Hospital-Acquired Infection due to Carbapenem-Resistant Enterobacteriaceae (CRE) 2012 , 105-115	
107	Laboratory evaluation of the CHROMagar KPC medium for identification of carbapenem-nonsusceptible Enterobacteriaceae. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011 , 70, 565-7	2.9 25
106	The effects of group 1 versus group 2 carbapenems on imipenem-resistant <i>Pseudomonas aeruginosa</i> : an ecological study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011 , 70, 367-72	2.9 34
105	<i>Pseudomonas aeruginosa</i> bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011 , 71, 38-45	2.9 25
104	Laboratory and clinical evaluation of screening agar plates for detection of carbapenem-resistant Enterobacteriaceae from surveillance rectal swabs. <i>Journal of Clinical Microbiology</i> , 2011 , 49, 2239-42	9.7 94
103	Containment of a country-wide outbreak of carbapenem-resistant <i>Klebsiella pneumoniae</i> in Israeli hospitals via a nationally implemented intervention. <i>Clinical Infectious Diseases</i> , 2011 , 52, 848-55	11.6 326
102	Predictors of rectal carriage of carbapenem-resistant Enterobacteriaceae (CRE) among patients with known CRE carriage at their next hospital encounter. <i>Infection Control and Hospital Epidemiology</i> , 2011 , 32, 497-503	2 57
101	Carbapenem-resistant <i>Klebsiella pneumoniae</i> in post-acute-care facilities in Israel. <i>Infection Control and Hospital Epidemiology</i> , 2011 , 32, 845-53	2 79
100	Dissemination of the <i>Klebsiella pneumoniae</i> carbapenemase in the health care settings: tracking the trails of an elusive offender. <i>MBio</i> , 2011 , 2,	7.8 13
99	Plasmid-encoded OXA-48 carbapenemase in <i>Escherichia coli</i> from Israel. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 672-3	5.1 41
98	Introduction of OXA-48-producing Enterobacteriaceae to Israeli hospitals by medical tourism. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 2763-6	5.1 54
97	A call for action: the application of The International Health Regulations to the global threat of antimicrobial resistance. <i>PLoS Medicine</i> , 2011 , 8, e1001022	11.6 57
96	Transfer of carbapenem-resistant plasmid from <i>Klebsiella pneumoniae</i> ST258 to <i>Escherichia coli</i> in patient. <i>Emerging Infectious Diseases</i> , 2010 , 16, 1014-7	10.2 103
95	Plasmid pKpQIL encoding KPC-3 and TEM-1 confers carbapenem resistance in an extremely drug-resistant epidemic <i>Klebsiella pneumoniae</i> strain. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 243-8	5.1 67
94	National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 5099-104	5.9 102
93	How to stem the tide of carbapenemase-producing enterobacteriaceae?: proactive versus reactive strategies. <i>Current Opinion in Infectious Diseases</i> , 2010 , 23, 327-31	5.4 57

92	Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing <i>Klebsiella</i> species in hospitalized patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 2010-6	5.9	61
91	Complete nucleotide sequence of KPC-3-encoding plasmid pKpQIL in the epidemic <i>Klebsiella pneumoniae</i> sequence type 258. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 4493-6	5.9	90
90	Carbapenem-resistant KPC-2-producing <i>Escherichia coli</i> in a Tel Aviv Medical Center, 2005 to 2008. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 2687-91	5.9	33
89	Worldwide diversity of <i>Klebsiella pneumoniae</i> that produce beta-lactamase blaKPC-2 gene. <i>Emerging Infectious Diseases</i> , 2010 , 16, 1349-56	10.2	249
88	Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing <i>Klebsiella pneumoniae</i> strains in Israel. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 3002-6	5.9	68
87	Molecular epidemiology of KPC-producing <i>Klebsiella pneumoniae</i> isolates in the United States: clonal expansion of multilocus sequence type 258. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 3365-70	5.9	421
86	Impact of quinolone restriction on resistance patterns of <i>Escherichia coli</i> isolated from urine by culture in a community setting. <i>Clinical Infectious Diseases</i> , 2009 , 49, 869-75	11.6	85
85	Ertapenem resistance among extended-spectrum-beta-lactamase-producing <i>Klebsiella pneumoniae</i> isolates. <i>Journal of Clinical Microbiology</i> , 2009 , 47, 969-74	9.7	51
84	Evaluation of PCR-based testing for surveillance of KPC-producing carbapenem-resistant members of the Enterobacteriaceae family. <i>Journal of Clinical Microbiology</i> , 2009 , 47, 3261-5	9.7	95
83	First report on a hyperepidemic clone of KPC-3-producing <i>Klebsiella pneumoniae</i> in Israel genetically related to a strain causing outbreaks in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 818-20	5.9	142
82	Gram-negative bacteremia upon hospital admission: when should <i>Pseudomonas aeruginosa</i> be suspected?. <i>Clinical Infectious Diseases</i> , 2009 , 48, 580-6	11.6	54
81	Detection of aac(6)-Ib-cr in KPC-producing <i>Klebsiella pneumoniae</i> isolates from Tel Aviv, Israel. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 718-22	5.1	33
80	A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. <i>Clinical Infectious Diseases</i> , 2009 , 49, 682-90	11.6	336
79	Carbapenem-resistant <i>Klebsiella pneumoniae</i> endocarditis in a young adult. Successful treatment with gentamicin and colistin. <i>International Journal of Infectious Diseases</i> , 2009 , 13, e295-8	10.5	22
78	Incidence of and preoperative risk factors for <i>Staphylococcus aureus</i> bacteremia and chest wound infection after cardiac surgery. <i>Infection Control and Hospital Epidemiology</i> , 2009 , 30, 242-8	2	19
77	Parental <i>Staphylococcus aureus</i> carriage is associated with staphylococcal carriage in young children. <i>Pediatric Infectious Disease Journal</i> , 2009 , 28, 960-5	3.4	28
76	Treatment options for multidrug-resistant <i>Acinetobacter</i> species. <i>Drugs</i> , 2008 , 68, 165-89	12.1	43
75	Carbapenem-resistant Enterobacteriaceae: a potential threat. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 300, 2911-3	27.4	205

74	Analogous oligo-acyl-lysines with distinct antibacterial mechanisms. <i>FASEB Journal</i> , 2008 , 22, 2652-61	0.9	57
73	Clinical and economic impact of common multidrug-resistant gram-negative bacilli. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 813-21	5.9	443
72	Factors associated with candidemia caused by non-albicans <i>Candida</i> species versus <i>Candida albicans</i> in the intensive care unit. <i>Clinical Infectious Diseases</i> , 2008 , 46, 1206-13	11.6	192
71	Isolation of imipenem-resistant <i>Enterobacter</i> species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 1413-8	5.9	159
70	Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible <i>Enterobacter cloacae</i> isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 2962-5	5.9	38
69	Predictors of carbapenem-resistant <i>Klebsiella pneumoniae</i> acquisition among hospitalized adults and effect of acquisition on mortality. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 1028-33	5.9	369
68	Dissemination of the CTX-M-25 family beta-lactamases among <i>Klebsiella pneumoniae</i> , <i>Escherichia coli</i> and <i>Enterobacter cloacae</i> and identification of the novel enzyme CTX-M-41 in <i>Proteus mirabilis</i> in Israel. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 289-95	5.1	39
67	Molecular and epidemiologic study of polyclonal outbreaks of multidrug-resistant <i>Acinetobacter baumannii</i> infection in an Israeli hospital. <i>Infection Control and Hospital Epidemiology</i> , 2007 , 28, 945-50	2	46
66	Raising standards while watching the bottom line: making a business case for infection control. <i>Infection Control and Hospital Epidemiology</i> , 2007 , 28, 1121-33	2	111
65	Improved antimicrobial peptides based on acyl-lysine oligomers. <i>Nature Biotechnology</i> , 2007 , 25, 657-9	44.5	211
64	High tigecycline resistance in multidrug-resistant <i>Acinetobacter baumannii</i> Authors Response. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 178-179	5.1	6
63	Surveillance cultures and duration of carriage of multidrug-resistant <i>Acinetobacter baumannii</i> . <i>Journal of Clinical Microbiology</i> , 2007 , 45, 1551-5	9.7	127
62	High tigecycline resistance in multidrug-resistant <i>Acinetobacter baumannii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 59, 772-4	5.1	187
61	Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in <i>Enterobacteriaceae</i> bacteraemia: a systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 913-20	5.1	448
60	First national surveillance of susceptibility of extended-spectrum beta-lactamase-producing <i>Escherichia coli</i> and <i>Klebsiella</i> spp. to antimicrobials in Israel. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007 , 57, 201-5	2.9	22
59	Emergence of KPC-2 and KPC-3 in carbapenem-resistant <i>Klebsiella pneumoniae</i> strains in an Israeli hospital. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 3026-9	5.9	198
58	Predictors of mortality in patients with bloodstream infection due to ceftazidime-resistant <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 1715-20	5.9	67
57	Utility of the VITEK 2 Advanced Expert System for identification of extended-spectrum beta-lactamase production in <i>Enterobacter</i> spp. <i>Journal of Clinical Microbiology</i> , 2006 , 44, 241-3	9.7	11

56	Endocarditis caused by extended-spectrum-beta-lactamase-producing <i>Klebsiella pneumoniae</i> : emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 3179-82	5.9	54
55	Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 2192-6	5.9	46
54	Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant <i>Escherichia coli</i> clones in Israel. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 3098-101	5.9	132
53	Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 1257-62	5.9	328
52	Antimicrobial resistance and patient outcomes: the hazards of adjustment. <i>Critical Care</i> , 2006 , 10, 164	10.8	20
51	Multidrug-resistant <i>Pseudomonas aeruginosa</i> : risk factors and clinical impact. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 43-8	5.9	419
50	Antibodies raised against N-terminal <i>Pseudomonas aeruginosa</i> flagellin prevent mortality in lethal murine models of infection. <i>International Journal of Molecular Medicine</i> , 2005 , 16, 165	4.4	5
49	The impact of methicillin resistance in <i>Staphylococcus aureus</i> bacteremia on patient outcomes: mortality, length of stay, and hospital charges. <i>Infection Control and Hospital Epidemiology</i> , 2005 , 26, 166-74	2	696
48	Impact of severity of illness bias and control group misclassification bias in case-control studies of antimicrobial-resistant organisms. <i>Infection Control and Hospital Epidemiology</i> , 2005 , 26, 342-5	2	38
47	The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. <i>Infection Control and Hospital Epidemiology</i> , 2005 , 26, 346-51	2	120
46	Update on <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> infections in the healthcare setting. <i>Current Opinion in Infectious Diseases</i> , 2005 , 18, 306-13	5.4	159
45	Multidrug-resistant <i>Acinetobacter baumannii</i> . <i>Emerging Infectious Diseases</i> , 2005 , 11, 22-9	10.2	189
44	Prior antimicrobial therapy and risk for hospital-acquired <i>Candida glabrata</i> and <i>Candida krusei</i> fungemia: a case-case-control study. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 4555-60	5.9	115
43	Evaluation of an accelerated protocol for detection of extended-spectrum beta-lactamase-producing gram-negative bacilli from positive blood cultures. <i>Journal of Clinical Microbiology</i> , 2005 , 43, 439-41	9.7	5
42	CTX-M-2 and a new CTX-M-39 enzyme are the major extended-spectrum beta-lactamases in multiple <i>Escherichia coli</i> clones isolated in Tel Aviv, Israel. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 4745-50	5.9	52
41	High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 2137-9	5.9	109
40	Extended-spectrum beta-lactamases among <i>Enterobacter</i> isolates obtained in Tel Aviv, Israel. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 1150-6	5.9	60
39	Fluoroquinolones protective against cephalosporin resistance in gram-negative nosocomial pathogens. <i>Emerging Infectious Diseases</i> , 2004 , 10, 94-9	10.2	18

38	Reference group choice and antibiotic resistance outcomes. <i>Emerging Infectious Diseases</i> , 2004 , 10, 1125-1132	11.6	86
37	Hospital-acquired infective endocarditis: should the definition be broadened?. <i>Clinical Infectious Diseases</i> , 2004 , 38, 843-50	11.6	58
36	Association between carriage of <i>Streptococcus pneumoniae</i> and <i>Staphylococcus aureus</i> in Children. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 292, 716-20	27.4	221
35	The magnitude of the association between fluoroquinolone use and quinolone-resistant <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> may be lower than previously reported. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 1934-40	5.9	29
34	Reply to Cicalini et al.. <i>Clinical Infectious Diseases</i> , 2004 , 39, 1085-1085	11.6	30
33	Glycopeptides are no more effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: a meta-analysis. <i>Clinical Infectious Diseases</i> , 2004 , 38, 1357-63	11.6	124
32	Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae?. <i>Clinical Microbiology and Infection</i> , 2004 , 10, 84-5	9.5	26
31	Epidemiological interpretation of antibiotic resistance studies - what are we missing?. <i>Nature Reviews Microbiology</i> , 2004 , 2, 979-83	22.2	78
30	Occurrence and phenotypic characteristics of extended-spectrum beta-lactamases among members of the family Enterobacteriaceae at the Tel-Aviv Medical Center (Israel) and evaluation of diagnostic tests. <i>Journal of Clinical Microbiology</i> , 2003 , 41, 155-8	9.7	39
29	Adverse clinical and economic outcomes attributable to methicillin resistance among patients with <i>Staphylococcus aureus</i> surgical site infection. <i>Clinical Infectious Diseases</i> , 2003 , 36, 592-8	11.6	714
28	Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant <i>Staphylococcus aureus</i> bacteremia. <i>Emerging Infectious Diseases</i> , 2003 , 9, 657-64	10.2	35
27	Fluoroquinolones and the risk for methicillin-resistant <i>Staphylococcus aureus</i> in hospitalized patients. <i>Emerging Infectious Diseases</i> , 2003 , 9, 1415-22	10.2	270
26	Studies of bloodstream infection outcomes: reading between the lines. <i>Infection Control and Hospital Epidemiology</i> , 2003 , 24, 884-6	2	11
25	Comparison of mortality associated with methicillin-resistant and methicillin-susceptible <i>Staphylococcus aureus</i> bacteremia: a meta-analysis. <i>Clinical Infectious Diseases</i> , 2003 , 36, 53-9	11.6	1519
24	The impact of antimicrobial resistance on health and economic outcomes. <i>Clinical Infectious Diseases</i> , 2003 , 36, 1433-7	11.6	408
23	Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 1882-6	5.9	36
22	Antibacterial properties of dermaseptin S4 derivatives with in vivo activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 689-94	5.9	115
21	Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 1619-28	5.9	125

20	Control-group selection importance in studies of antimicrobial resistance: examples applied to <i>Pseudomonas aeruginosa</i> , Enterococci, and <i>Escherichia coli</i> . <i>Clinical Infectious Diseases</i> , 2002 , 34, 1558-63	11.6	144
19	Health and economic outcomes of the emergence of third-generation cephalosporin resistance in <i>Enterobacter</i> species. <i>Archives of Internal Medicine</i> , 2002 , 162, 185-90		195
18	Health and economic outcomes of vancomycin-resistant enterococci. <i>Archives of Internal Medicine</i> , 2002 , 162, 2223-8		183
17	Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant <i>Enterococcus</i> . <i>Emerging Infectious Diseases</i> , 2002 , 8, 802-7	10.2	125
16	Clinical isolation and resistance patterns of and superinfection with 10 nosocomial pathogens after treatment with ceftriaxone versus ampicillin-sulbactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2001 , 45, 275-9	5.9	19
15	Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli. <i>Clinical Infectious Diseases</i> , 2001 , 33, 1462-8	11.6	138
14	Risk factors for emergence of resistance to broad-spectrum cephalosporins among <i>Enterobacter</i> spp. <i>Antimicrobial Agents and Chemotherapy</i> , 2001 , 45, 2628-30	5.9	132
13	Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. <i>Clinical Infectious Diseases</i> , 2001 , 32, 1055-61	11.6	215
12	Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. <i>Circulation</i> , 2000 , 101, 2916-21	16.7	404
11	SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse <i>Serratia marcescens</i> strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 3035-9	5.9	108
10	Risk factors for recovery of ampicillin-sulbactam-resistant <i>Escherichia coli</i> in hospitalized patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 1004-9	5.9	49
9	Clinical significance and antibiotic resistance patterns of <i>Lemnorea</i> spp., an emerging nosocomial pathogen. <i>Journal of Clinical Microbiology</i> , 2000 , 38, 3036-8	9.7	16
8	Emergence of antibiotic-resistant <i>Pseudomonas aeruginosa</i> : comparison of risks associated with different antipseudomonal agents. <i>Antimicrobial Agents and Chemotherapy</i> , 1999 , 43, 1379-82	5.9	420
7	The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: a meta-analysis. <i>Archives of Internal Medicine</i> , 1999 , 159, 2461-8		107
6	Risk factors for nosocomial candiduria due to <i>Candida glabrata</i> and <i>Candida albicans</i> . <i>Clinical Infectious Diseases</i> , 1999 , 29, 926-8	11.6	65
5	Health and economic outcomes of antibiotic resistance in <i>Pseudomonas aeruginosa</i> . <i>Archives of Internal Medicine</i> , 1999 , 159, 1127-32		266
4	Epidemiology and clinical outcomes of patients with multiresistant <i>Pseudomonas aeruginosa</i> . <i>Clinical Infectious Diseases</i> , 1999 , 28, 1128-33	11.6	142
3	Nosocomial Superinfections with Gram-Negative Pathogens and Quinolone Resistance after Treatment with Ciprofloxacin vs Ofloxacin. <i>Drugs</i> , 1999 , 58, 128-129	12.1	

- 2 Failure of quality control measures to prevent reporting of false resistance to imipenem, resulting in a pseudo-outbreak of imipenem-resistant *Pseudomonas aeruginosa*. *Journal of Clinical Microbiology*, **1998**, 36, 595-7 9.7 11
- 1 Imipenem-resistant *Pseudomonas aeruginosa*: risk factors and antibiotic susceptibility patterns. *Clinical Infectious Diseases*, **1997**, 25, 1094-8 11.6 143